HC Wainwright & Co. has reiterated its buy rating for Capricor Therapeutics (CAPR.US), with a target price of $40.00 buy.
HC Wainwright & Co.：重申Capricor Therapeutics(CAPR.US)评级，由买入调整至买入评级, 目标价40.00美元。
HC Wainwright & Co. : The Capricorn Therapeutics (CAPR.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $40.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.